[Endocrine therapy of prostatic cancer].
Response rate of prostatic cancer to endocrine therapy is approximately 80%, but more than half of responders show relapse by five years. Factors influencing prognosis are histological grade, stage, effect of elevated acid phosphatase, and androphilic protein observed histochemically. Relapse may be attributable to progression and clonal selection.
D000368:Aged; D000727:Androgen-Binding Protein / Q000032:analysis; D002369:Castration; D003131:Combined Modality Therapy; D004967:Estrogens / Q000627:therapeutic use*; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D011944:Receptors, Androgen / Q000032:analysis
D000727:Androgen-Binding Protein; D004967:Estrogens; D011944:Receptors, Androgen